374 related articles for article (PubMed ID: 27029727)
21. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
22. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
23. Emerging biomarkers in the detection and prognosis of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
[TBL] [Abstract][Full Text] [Related]
24. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
25. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
[TBL] [Abstract][Full Text] [Related]
26. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer screening.
Sikaris K
Pathology; 2012 Feb; 44(2):99-109. PubMed ID: 22198258
[TBL] [Abstract][Full Text] [Related]
28. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
29. Landmarks in prostate cancer screening.
Schröder FH
BJU Int; 2012 Oct; 110 Suppl 1():3-7. PubMed ID: 23046034
[TBL] [Abstract][Full Text] [Related]
30. Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.
Barnett CL; Tomlins SA; Underwood DJ; Wei JT; Morgan TM; Montie JE; Denton BT
Med Decis Making; 2017 Oct; 37(7):815-826. PubMed ID: 28363265
[TBL] [Abstract][Full Text] [Related]
31. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
Schmid M; Hansen J; Chun FK
Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
[TBL] [Abstract][Full Text] [Related]
32. Landmarks in prostate cancer diagnosis: the biomarkers.
Artibani W
BJU Int; 2012 Oct; 110 Suppl 1():8-13. PubMed ID: 23046035
[TBL] [Abstract][Full Text] [Related]
33. Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis.
Rodriguez JF; Eggener SE
Radiol Clin North Am; 2018 Mar; 56(2):187-196. PubMed ID: 29420975
[TBL] [Abstract][Full Text] [Related]
34. [Focus on the screening for prostate cancer by PSA].
Roumeguère T; Van Velthoven R
Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
[TBL] [Abstract][Full Text] [Related]
35. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
[TBL] [Abstract][Full Text] [Related]
36. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
Murray NP; Reyes E; Tapia P; Orellana N; Dueñas R; Fuentealba C; Badinez L
Arch Esp Urol; 2011 Dec; 64(10):961-71. PubMed ID: 22228894
[TBL] [Abstract][Full Text] [Related]
38. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
39. Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients.
Pepe P; Aragona F
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):316-9. PubMed ID: 20714341
[TBL] [Abstract][Full Text] [Related]
40. [Practice of early detection of prostate cancer : Descriptive survey in preparation for the PSAInForm study].
Simbrich A; Semjonow A; Donner-Banzhoff N; Hense HW
Urologe A; 2018 Jun; 57(6):702-708. PubMed ID: 29671079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
